Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) is reporting fourth quarter financial results on Monday 23rd November 2020, after market close.
According to analysts surveyed by Thomson Reuters, ENTA is expected to report 4Q20 loss of $ 0.95 per share from revenue of $ 25.74 million.
For the full year, analysts anticipate top line of $ 124.61 million, while looking forward to loss of $ 1.3 per share bottom line.
Previous Quarter Performance
Enanta Pharmaceuticals, Inc. unveiled loss for the third quarter of $ 0.71 per share, from the revenue of $ 18.65 million. The quarterly revenues shrunk 60.30 percent compared with the same quarter last year. Wall street analysts are predicting, ENTA to report 3Q20 loss of $ 0.84 per share from revenue of $ 26.32 million. The bottom line results beat street analysts by $ 0.13 or 15.48 percent, at the same time, top line results fell short of analysts by $ 7.67 million or 29.14 percent.
Stock Performance
Shares of Enanta Pharmaceuticals, Inc. traded low $ -0.58 or -1.31 percent on Friday, reaching $ 43.57 with volume of 145.80 thousand shares. Enanta Pharmaceuticals, Inc. has traded high as $ 44.38 and has cracked $ 43.14 on the downward trend
According to the previous trading day, closing price of $ 43.57, representing a 14.97 % increase from the 52 week low of $ 38.40 and a 34.96 % decrease over the 52 week high of $ 67.88.
The company has a market capital of $ 874.54 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Enanta Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 23rd November 2020, to discuss its 4Q20 financial results with the investment community. The participants may dial, 855-840-0595 Toll Free, (United States) or 518-444-4814 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.enanta.com
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc.
